Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 32Head & Neck 1CNS 1

Conditions

Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 5Docetaxel 4ulixertinib 2Trastuzumab 2Radiotherapy 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Irinotecan 2Fluorodeoxyglucose F18 2Carboplatin 2Capecitabine 2Bevacizumab 2trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1tanespimycin 1spartalizumab 1sonidegib 1sargramostim 1sapanisertib 1relatlimab 1regorafenib 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Epirubicin × CNS × Clear all
NCT00021047 2012-03-08

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
CNSGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡